Alkermes PLC (ALKS)
24.05
+0.19
(+0.80%)
USD |
NASDAQ |
May 03, 16:00
24.06
0.00 (0.00%)
After-Hours: 20:00
Alkermes Research and Development Expense (Quarterly): 67.61M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 67.61M |
December 31, 2023 | -20.76M |
September 30, 2023 | 97.14M |
June 30, 2023 | 100.79M |
March 31, 2023 | 63.77M |
December 31, 2022 | -16.55M |
September 30, 2022 | 100.43M |
June 30, 2022 | 92.87M |
March 31, 2022 | 95.95M |
December 31, 2021 | -17.23M |
September 30, 2021 | 118.41M |
June 30, 2021 | 97.47M |
March 31, 2021 | 92.27M |
December 31, 2020 | 112.11M |
September 30, 2020 | 94.98M |
June 30, 2020 | 94.22M |
March 31, 2020 | 93.28M |
December 31, 2019 | 198.16M |
September 30, 2019 | 107.67M |
June 30, 2019 | 104.44M |
March 31, 2019 | 102.57M |
December 31, 2018 | 108.97M |
September 30, 2018 | 101.26M |
June 30, 2018 | 106.82M |
March 31, 2018 | 108.35M |
Date | Value |
---|---|
December 31, 2017 | 104.49M |
September 30, 2017 | 104.41M |
June 30, 2017 | 99.15M |
March 31, 2017 | 104.84M |
December 31, 2016 | 89.62M |
September 30, 2016 | 99.44M |
June 30, 2016 | 97.01M |
March 31, 2016 | 101.07M |
December 31, 2015 | 93.69M |
September 30, 2015 | 92.56M |
June 30, 2015 | 87.88M |
March 31, 2015 | 70.28M |
December 31, 2014 | 74.43M |
September 30, 2014 | 78.26M |
June 30, 2014 | 67.21M |
March 31, 2014 | 52.14M |
September 30, 2013 | 45.95M |
June 30, 2013 | 33.46M |
March 31, 2013 | 35.80M |
December 31, 2012 | 31.32M |
September 30, 2012 | 35.09M |
June 30, 2012 | 37.81M |
March 31, 2012 | 45.19M |
December 31, 2011 | 40.49M |
September 30, 2011 | 28.16M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-20.76M
Minimum
Dec 2023
198.16M
Maximum
Dec 2019
83.85M
Average
95.47M
Median
Research and Development Expense (Quarterly) Benchmarks
Endo International PLC | 28.14M |
Jazz Pharmaceuticals PLC | 222.85M |
Medtronic PLC | 695.00M |
Perrigo Co PLC | 29.60M |
Iterum Therapeutics PLC | 9.744M |